AICDA and acute lymphoblastic leukemia: AID is also expressed in Ph+ ALL patients, who show an increased mutation frequency of oncogenes and TSGs, such as MYC, BCL6, and p16, which may be relevant to the unfavorable prognosis in this subset of ALL [7].